Acrivon Therapeutics Inc. has announced the approval of a new equity award for an employee under its 2023 Inducement Plan. The award consists of stock options to purchase 225,000 shares of Acrivon common stock, with an exercise price set at the closing price on the grant date, October 1, 2025. The options vest 25% after one year from the month following the employee's start date, with the remaining options vesting in equal monthly installments over the subsequent three years.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acrivon Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9538757-en) on October 01, 2025, and is solely responsible for the information contained therein.